Survival for patients with high-risk acute lymphoblastic leukemia ranges from two or three months to several years. Survival in acute lymphoblastic leukemia varies widely in children and adults.
Survival in acute lymphoblastic leukemia is related to age, risk stratification of the disease, and treatment, and should be analyzed on a problem-by-problem basis.
Children up to 10 years of age with acute lymphoid leukemia have a fairly high remission rate, and patients with standard long courses of chemotherapy have a high cure rate. In contrast, middle-aged and elderly patients with acute gonorrhea have significantly lower efficacy, but in the case of Philadelphia chromosome-positive patients, tyrosine kinase inhibitors (e.g., imatinib) can be added, at which point efficacy can be substantially improved again.
Adult high-risk patients with acute gonorrhea have poor chemotherapy efficacy and relapse quickly, and the relapse rate after allogeneic hematopoietic stem cell transplantation is high, with only a few patients surviving for a long period of time. All of the above drugs should be used in accordance with medical advice.